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Introduction
The combination therapy with interferon (INF) and ribavi-
rin became the standard treatment for hepatitis C virus 
(HCV) and was/is considered to be effective in eradicating 
the infection even in more complex cases (e.g. patients with 
HIV or those with advanced cirrhosis; Keating and Curran, 
2003). However, the INF-based treatments were also found 
to be associated with significant toxicities and a wide array 
of physical and psychiatric side effects negatively affecting 
patients’ quality of life (Cornberg et al., 2002; Fontana, 
2000). Fatigue, headaches, nausea, anger outbursts, depres-
sion, irritability and insomnia were the most frequently 
indicated side effects in patients receiving INF-based ther-
apy (Fried, 2002; Monji et al., 1998). Those adverse effects 
made the adherence to therapies extremely difficult and for 
many patients were often main reasons for discontinuing 
the treatment (e.g. Bernstein et al., 2002).
More recently, HCV treatment has chartered new terri-
tory with the introduction of direct-acting antivirals 
(DAAs). Such INF-free treatment regimens constitute a 
new improved opportunity for treatment in patients with 
HCV, particularly in those for whom previous therapies 
were intolerable or ineffective. These new therapies not 
only shorten treatment duration to 12 weeks but also show 
significant and sustained improvements in patient-reported 
outcomes (even within the first 4 weeks of the therapy com-
mencing; Younossi et al., 2016). Perhaps, most importantly, 
DDAs have achieved sustained virological response (SVR) 
rates exceeding 90 per cent, leading to fewer side effects 
and simplified drug administration (AASLD/IDSA HCV 
‘It’s been a long haul, a big haul, but 
we’ve made it’: hepatitis C virus 
treatment in post-transplant patients 
with virus recurrence: An interpretative 
phenomenological analysis
Anna Krzeczkowska1, Paul Flowers2, Zoe Chouliara3,  
Peter Hayes4 and Adele Dickson2
Abstract
The lived experience of both interferon-based and new interferon-free treatments in patients with hepatitis C virus 
remains understudied. To explore their journey through hepatitis C virus treatment, we interviewed seven post-
transplant patients with recurrent hepatitis C virus. Three themes were identified using interpretative phenomenological 
analysis. Participants reported an ongoing sense of ontological uncertainty characterized by lack of control over their 
condition and treatment. Furthermore, an apposition of scepticism and hope accompanying each stage of hepatitis C 
virus treatment was described. A staged approach to psychological intervention tailored to the needs of the patient and 
their associated ‘stage’ of hepatitis C virus treatment was recommended.
Keywords
direct-acting antivirals, hepatitis C virus, interpretative phenomenological analysis, liver transplant, virus recurrence
1University of Strathclyde, UK
2Glasgow Caledonian University, UK
3Edinburgh Napier University, UK
4The University of Edinburgh, UK
Corresponding author:
Anna Krzeczkowska, University of Strathclyde, 40 George Street, 
Glasgow G1 1QE, UK. 
Email: anna.krzeczkowska@strath.ac.uk
792673 HPO0010.1177/2055102918792673Health Psychology OpenKrzeczkowska et al.
research-article20182018
Report of Empirical Study
2 Health Psychology Open 
Guidance Panel, 2015; Afdhal et al., 2014). However, 
despite the availability and effectiveness of DAAs, HCV 
remains a leading cause of cirrhosis and hepatocellular car-
cinoma, which results in graft failure or second transplant 
in post-transplant patients with HCV recurrence (Goossens 
and Hoshida, 2015).
This population of transplant recipients is at increased 
risk of developing hepatocellular carcinoma, graft loss and 
premature death. Several trials with DAAs have shown 
promising results and their safety and efficacy in a real-world 
cohort of post-transplant patients has been verified (e.g. 
Brown et al., 2016; Kwo et al., 2014). Indeed, recent studies 
on DAAs regimens have focused particularly on post-trans-
plant patients with genotype 1; historically considered as the 
most difficult type to treat. The results have shown SVR 
rates of 81–100 per cent (Pungpapong et al., 2015).
Despite the promising results, the cost and limited access 
to the DAAs regimens remain main global barriers of eradi-
cating infection and disease progression (Fung, 2015; 
Hutchinson et al., 2015; Marshall et al., 2018). These barri-
ers evoke debate regarding cost-effectiveness of post-trans-
plant DAAs regimens, revealing clear monetary benefits, 
but only in terms of patients with advanced cirrhosis 
(Carrion et al., 2016; Samur et al., 2018). A delay in provid-
ing patients with effective treatment at this severe stage of 
the disease might impose additional costs on the health care 
budget, related to the decision about retransplantation 
(Bentley and Phillips, 2017; National Services Division, 
NHS, 2016). This invasive medical procedure is not only 
cost-intensive but it also imposes on patients’ continuous 
experience of stress and anxiety (Annema et al., 2015). The 
uncertainty associated with the transplant process, graft 
rejection and potential death are key concerns in the lives of 
patients with recurrent HCV following liver transplant.
Furthermore, patients’ decision-making about treatment 
can be influenced by psychological and social factors such 
as risk-benefit trade-offs, protected values and the recom-
mendations of the health providers (Fraenkel et al., 2005). 
An important role plays also patients’ perception of the 
severity of HCV that can motivate them to take protective 
actions, as defined in many theories of health behaviour 
(Rimal and Real, 2003; Rogers, 1975; Rosenstock, 1974). 
However, according to the Health Belief Model (Rosenstock, 
1974), the perceived seriousness of their condition might be 
based not only on medical information and knowledge but 
also on their past experiences of treatment and the illness. In 
this sense, their beliefs are susceptible to biases and some-
times might appear unjustified (Merz and Fischhoff, 1990). 
Therefore, physicians by helping patients with HCV reach 
informed decisions and offering explanation of treatment 
alternatives and their possible outcomes may enhance their 
efficacy beliefs in regard to the new treatment regimens.
Given that not all HCV patients are currently offered to 
receive the DAAs regimens, gaining insight into how the 
range of HCV treatments per se is perceived and 
experienced by patients can be extremely important in 
planning and managing professional care and information 
provision within inpatient and outpatient clinics. The aim 
of this study was, therefore, to explore the lived experience 
of a prolonged journey through HCV treatment in this dis-
tinct population, including pre-transplant pegylated INF 
and/or ribavirin trials, liver transplantation and recently 
introduced INF-free therapies.
Previous qualitative studies tended to describe the lived 
experience in patients with HCV by concentrating on one 
stage of treatment at a time (e.g. Dudley et al., 2007; Hopwood 
et al., 2006). This study sought to illuminate the patients’ per-
spective in light of a chronological journey through their HCV 
treatment. To date, only one qualitative study has addressed 
the lived experience of INF-free HCV treatments (Whiteley 
et al., 2016), but the authors did not explore how the availabil-
ity of DAAs could shape experiences of particular patient 
groups such as patients with recurrent HCV following liver 
transplant. This study attempts to extend extant HCV literature 
by highlighting the lived idiographic experiences of percep-
tions, anticipations and hopes around new antiviral therapy, 
both in post-transplant patients who have received such ther-
apy and in those who have not yet been offered the new treat-
ment. This will be achieved by employing interpretative 
phenomenological analysis (IPA; Smith et al., 2009).
Method
Participants
Seven post-liver transplant patients with recurrent HCV 
were recruited via a hospital-based outpatient clinic in 
Scotland. All participants were male aged between 53 and 
68 years (M = 57.3 years). Homogeneity of the sample in 
terms of gender was not purposive, and no female patients 
responded to research invitations. Participants received 
liver transplant between 9 and 18 months (M = 12.6) before 
the commencement of this study. Two of the participants 
completed INF-free treatment and cleared the virus; the 
remaining five participants had not yet been listed for this 
particular therapy at the time of the interview. All partici-
pants had received INF-based treatment for HCV pre-trans-
plant. Participants were not able to recall either a number or 
specific name of antiviral, INF-based treatments they 
underwent prior to liver transplant. Participants were 
recruited from various geographical locations in Scotland.
Procedure and interview
Ethical approval for the study was sought and obtained 
from Edinburgh Napier University Research Ethics 
Committee (where the first author was based at that time) 
and the West of Scotland National Health Service (NHS) 
Ethics Committee. The interviews took place between 
January and May 2015.
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Recruitment packs were either sent directly to patients 
via post (n = 18) or were distributed by the transplant co-
ordinators during routine appointments at the outpatient 
clinics (n = 10). The first and last authors’ details were pro-
vided in order for potential participants to contact the 
research team and indicate their willingness to partake.
Inclusion criteria were that participants should be adults 
over 18 years of age who (a) had received a liver transplant 
primarily due to HCV at least 6 months prior their inter-
view, (b) were no more than 36 months post transplant and 
(c) were fluent in the English language. Patients excluded 
from this study were individuals who (a) had not been seen 
routinely at a hospital, (b) had been currently receiving 
methadone treatment, (c) had received more than one trans-
plant, (d) had been imprisoned and (e) had been deemed by 
the lead hepatologist as being too emotionally fragile or 
possessing a current psychosis or other mental health con-
dition. All patients with HCV underwent a psychiatric 
assessment prior to transplant and then regularly attended 
follow-up appointments with their hepatologist. This pro-
vided the transplant co-ordinators with sufficient informa-
tion about the patient’s current mental condition and how, if 
at all, it had changed after the liver transplantation.
The interviews were conducted by the first author and took 
place either at the hospital (n = 6) or in the participants’ own 
homes (n = 1). The interviews lasted for between 32 and 
68 minutes (M = 50.6) and were recorded on a digital voice 
recorder. Written consent was obtained from the participants 
prior to the commencement of their interviews. The inter-
viewer was trained in collecting qualitative data by the last 
and third authors who are experts in using IPA methodology.
A semi-structured interview schedule was prepared prior 
to the interview and included open-ended questions such as 
‘Tell me about your experience of recurrent HCV’ and 
‘What impact (if at all) has the diagnosis had on your life?’ 
The interview schedule was not followed in a rigid way, 
and instead, a process of reflecting (e.g. ‘you said there that 
…’) and probing (e.g. ‘tell me more about that’) was 
adopted. This allowed the participants to direct the content 
of the interview and prioritize issues which they felt were 
central to the topic under investigation. Interviews were 
then transcribed verbatim and were analysed using IPA.
Analysis
IPA was adopted for this study as it is not concerned with 
generating an objective account of the phenomenon under 
investigation, but foregrounds participants’ subjective 
records of their world. Participants explore and interpret 
their own experiences, whereas the researcher applies the 
analytic approach to make sense of their biographic stories. 
IPA provides a ‘voice’ for the lived experiences of a given 
clinical population and allows the analyst interpretative 
engagement with the individual’s rich narrative account 
(Smith, 1996). This study was carried out in accordance 
with principles for validity of qualitative research defined 
by Yardley (2000). Sensitivity to context was demonstrated 
by taking into account existing theoretical and empirical 
literature and by using IPA as most appropriate methodol-
ogy to capture the meaning of the phenomenon under 
investigation. Rigour and commitment were demonstrated 
by the author’s personal engagement in the process of 
recruitment, data collection and engaging in the text analy-
sis. Authors were also focused on idiographic engagement 
in data analysis, illustrating particularities of individual 
cases by using appropriate quotes, but they did also empha-
size the importance of shared experiences in formulating 
the major themes.
The first author conducted the analysis with the last 
author also independently analysing a sample of transcripts. 
The last and third authors carried out credibility checks on 
both coding and interpretation. The process of analysis 
involved several key stages as suggested by Smith et al. 
(2009). These included: (a) reading and re-reading the tran-
script, (b) making initial descriptive notes, (c) transforming 
initial comments into emergent themes, (d) looking for con-
nections between the identified themes and defining master 
themes, (e) moving to the next interview and repeating all 
the steps of the analysis and (f) looking for connections 
between the cases and developing master themes for the 
whole sample. The extracts presented herein have been 
selected as they represent the most powerful or insightful 
quotes and capture the very essence of the theme.
This study presents three inter-related master themes: (a) 
‘It was a way of moving forward to the next stage of trials’: 
pre-transplant treatment; (b) ‘I started to go downhill’: expe-
riencing liver transplant and (c) ‘I am going to go through it 
all again, and it’s that that gets you’: virus recurrence post-
transplant. It is noteworthy that in the extracts which follow, 
[…] represents missing text. Pseudonyms have been incor-
porated throughout to preserve participant anonymity.
Results
The HCV treatment journey was reported in three key stages 
by participants. We present this journey in chronological 
order, beginning with an exploration of a variety of pre-
transplant treatment, mostly containing INF. Detrimental 
side effects affecting physical and social functioning are 
highlighted. We then progress to the tentative period of 
waiting on the transplant list for a suitable organ to become 
available. Finally, we focus on the experience of virus recur-
rence post-transplant.
‘It was a way of moving forward to the next 
stage of trials’: pre-transplant treatment
All patients in this study were diagnosed with HCV when 
INF-based therapy was the only available treatment option. 
Following diagnosis, participants engaged in a series of 
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medical interventions, often within drug trials, in a bid to 
prolong their lives and potentially cure their condition. 
Given the limited options available at that time, partici-
pants suggested that any treatment was ‘better than noth-
ing’ and that engagement with drug trials might enable 
them to live long enough for further drug development:
One of them, one of the trials was very bad, but I was quite 
happy to go into these trials, because well sort of thing that was 
there was a chance, and also, it was a way of moving forward 
to the next stage of trials etc. (Gus)
Although continually facing treatment-related adversi-
ties, participants were prepared to endure ‘almost-any-
thing’. Trials offered hope and a sense of control over their 
future. Engaging in this ‘trial’ process provided participants 
with an automatic eligibility for future drug trials, drugs 
which they hoped would perhaps be more efficient and 
eventually successful. Engaging in these treatment trials, 
however, offered false and short-lived hope as the ongoing, 
resilient nature of the infection became apparent:
The doctor said there was a new treatment coming out, if you 
wanted to try it. […] it took away – it took the Hep C away. But 
it took it away for about two to four weeks. Then it came back 
with a vengeance. (Ted)
Ted’s account highlights his apparently futile battle to 
clear his virus. There is a sense of Ted’s resigned disap-
pointment and helplessness within this extract. Equally, the 
array of side effects which accompanied these early treat-
ments was often accompanied by feelings of loss of control. 
Participants reported being both physically and psychologi-
cally ill:
The treatment itself was horrendous. You were sick, you were 
in depression, you were angry, and you didn’t want to talk to 
anybody. I stayed in my bed. The smallest little thing just set 
you off. You were shouting at the kids, you were shouting at 
the wife, but you were up – sometimes you were up but the 
majority of the time you were down. You would feel as though 
you had a major flu attack. It was – you were sweating, you 
were cold. So, it was really, really bad. (Eric)
Here, Eric appears ‘changed’ in some way; his emo-
tional outbursts are uncharacteristic and uncontrollable. His 
use of the third person to describe himself is perhaps indic-
ative of how these early treatments transformed his sense of 
self.
Unlike Eric, many other participants reported decreased 
self-awareness in relation to their treatment-related aggres-
sive outbursts. They appeared to rely on reports from 
friends and relatives, rather than on their own firsthand rec-
ollections. Most of the participants also struggled to iden-
tify themselves with the behaviours they displayed as a 
result of INF treatment. In the interviews, they seemed to 
seek an escape from their past actions, by emphasizing that 
it was not them who acted so impulsively, because they 
were ‘not like that’. The side effects seemed to overpower 
them and fracture a sense of the continuity of self:
There was difficult to understand what was happening to you, 
you know, but it wasn’t something that was made you are 
going to kill somebody, you know… nothing like that or go 
fighting or nothing, just felt not totally in control, which was 
an unusual thing for me. (Gus)
However ‘horrendous’ or debilitating the relentless, 
unsuccessful treatments were, it did not prevent or discour-
age participants from exploring further treatment options as 
they became available. Facing their own premature mortal-
ity, participants repeatedly put their lives in the hands of 
others in a desperate and all-too-frequent bid for survival.
‘I started to go downhill’: experiencing liver 
transplant
Living with uncertainty in relation to treatment opportuni-
ties and outcomes (as highlighted in the previous theme) 
was further heightened by a rapid deterioration in physical 
functioning. For many patients, advanced symptomatology 
was pivotal in confronting the inevitability of an organ 
transplant: an eventuality they had attempted to repress in 
previous years:
I suppose in a way you always wondered what would happen, 
how you would feel and everything. But I always took the 
attitude just get on with life. But then, when I started to go 
downhill after that, you know, they had mentioned you know a 
number of years before, you know this … I always knew there 
was always a transplant at the end of it, even if they didn’t 
work the treatments now, there is always a chance of transplant. 
I didn’t go into, you know, what that meant really, until when I 
started go downhill. (Gus)
When faced with the reality of a transplant as the only 
life-saving option, participants were then confronted with a 
series of related, subsequent challenges and uncertainties. 
Uncertainty around if and when they would receive a trans-
plant came to fruition. Participants reported becoming 
impatient and frustrated questioning the meaning of being 
kept ‘on hold’:
Why is it taking so long? Why is it taking them two months to 
write this? Why am I not there? Why is it taking so long? And 
when you think back it wasn’t that long but it’s long to me 
because it’s another two months down the line where I should 
have started two months. Who knows what lengths of time that 
you are going to be on the list? Nobody knows. (Eric)
Eric’s recollections highlight how felt lost and abandoned, 
desperate for information and reassurance. He, like the 
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other participants, reported feeling alone, vulnerable and 
fragile in this critical moment, their lives literally ‘hanging 
in the balance’. There is a palpable sense of their helpless-
ness here, and the participants’ fate lay in the hands of their 
medical teams.
In contrast, feelings of relief, calm and elation accompa-
nied the news that they had been placed on the transplant 
list. The relief of the long-awaited decision was for some 
participants overwhelming awaking hope for the future:
They told me, you’ve been accepted, you’re on the list and I 
just broke down, totally. I think, I’m going to start getting my 
life back here. Then of course you don’t know how long 
you’ve got to wait, it’s just your luck I suppose. (Jimmy)
For Jimmy, the opportunity for transplant first brought 
unadulterated relief and hope for the future yet this was short 
lived. Soon after worry, fear and eschatological thinking 
occurred. Hope was increasingly stained with a profound 
fear of dying while on the waiting list. The uncertainty of 
receiving an organ in time led to extreme vulnerability and 
helplessness – their survival lay far beyond their control:
They said, ‘You might die on the operating theatre. Your liver 
might be rejected so you’ve got to go onto the super list, and 
that’s a case of you first to get a liver’. That’s quite scary as 
well, saying if I’m going for a liver transplant and that liver 
doesn’t take, how am I going to survive until they get me a new 
one because I don’t – you’ve not got that long to go. I don’t 
know if it’s a day or two days, I don’t know. But it’d be a case 
of I’m first to get a liver in the United Kingdom and it’s pretty 
scary. (Ted)
Analysis showed a clear sense of the multiple hurdles 
that were needed to survive hepatitis C infection. The grav-
ity and precariousness of the situation is obvious. A sense 
of the ongoing ontological uncertainty runs through Ted’s 
account and his persistent feeling of helplessness.
Participants seemed to have no choice but to undergo the 
surgery hoping for the positive outcome. There is no expec-
tation or anticipation of what the outcome would be or 
would not be. What counts for them is here and now the 
time of receiving new liver. However, the sense of accept-
ance and calmness does not last long after receiving the call 
to hospital. When they were taken to the operating theatre, 
fears of not surviving accelerated:
The worrying one is when you’re actually on your way there 
and – in your head, you know what to expect, but you don’t 
know. And when you get taken down, on the way through it 
and when you’re getting taken down in that theatre, you think 
to yourself, is this it? Is this my last breath sort of thing? 
(Jimmy)
Again, Jimmy’s extract reveals a stark realization of his 
own mortality and the fragility of his future at that moment 
in time. Here, everything appears suspended, where Jimmy 
is fixed on this one moment, this one final hope for sur-
vival, as his life entirely depends on others.
Some participants reframed the seriousness of the situa-
tion they were in, by reassuring themselves that they were 
‘strong enough to get through the operation’. Conversely, 
others appeared to accept the worst-case scenario, assign-
ing the outcome to predestination, something that seemed 
to be beyond their control leaving them only with prayers 
and hope. By accepting the fact that their survival was 
beyond their control, they adopted a fatalistic approach:
So maybe something happened but I also said when it happened 
… it happened. This is Allah brings, Allah, God, so if it’s 
happen it will happen but we’ll pray to God and something 
happen better for me. That was the only hope. (Harry)
I’m going to have to go through it all again,  
and it’s that that gets to you: virus recurrence 
post-transplant
Even a successful transplant could not alleviate feelings of 
uncertainty for many of the participants. HCV recurrence 
was ‘sort of hanging over’ participants, like ‘a shadow’, a 
‘constant reminder’ that they would perhaps never fully 
recover or ‘get rid of their illness’:
I don’t sleep at night because it’s going through your head all 
the time. […] knowing that you’ve still got it. Knowing you’ve 
had the transplant, is it just going to waste because you’re 
going to die of Hep C sort of thing, or you know, is it ruining 
this [graft] further? Am I going to have to go and get another, 
and wait until – I’m going to have to go through it all again, 
and it’s that that gets to you. (Jimmy)
The fear of organ rejection and dying were profound and 
led to assertion that receiving the transplant was in vain. A 
vision of burdensome process of another transplant became 
more real and preyed on participants’ mind. However, feel-
ings of despair and helplessness were balanced or even out-
weighed by the possibility for a new cure. DAAs fuelled 
new foundations of hope for almost certain recovery:
I know there are new treatments [DAAs] out there but this one 
is meant to be […] much better. It’s got like a 95%+ success 
rate especially with the genotype 1 which I have. […] hopefully 
the new drug will get its license and they will be able to say, 
‘You can have it’. (Eric)
Participants seemed to associate new treatments with 
something that could only ‘improve things’ and prevent 
them from suffering ‘badly’. The cure regained and intensi-
fied a sense of future possibilities in their lives. The possi-
bility of clearing the virus seemed to restore their positive 
attitude to life and have the potential to erase everything 
that made their lives a constant struggle:
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So, when I become healthy I can do a job. I can enjoy my life 
… enjoy the world. I will get well and there will be no 
complications, no problems. (Harry)
The participants’ hopes for a disease-free life seemed to 
be slightly counterbalanced by fears of detrimental side 
effects of DAAs. Most of the participants tended to look 
back and identify situations that were burdensome and pre-
vented their adherence to the previous treatments and virus 
clearance. However, no matter how detrimental were the 
effects of the past drugs accessed through trials, they 
seemed to be desperate to receive it anyway and put them-
selves ‘forward for anything’:
It depends how bad the side-effects were. But if I thought I 
could live with them then I would carry on, it’s only twelve 
weeks. I mean it sounds a long time, but it’ll be worth it in the 
end I suppose. […] So, I’m like a guinea pig I think, so you 
wait and see how that goes. I’m going to give it a bash, if it’s 
going to get rid of the Hep C I’ll give it a go. As long as it 
doesn’t damage this liver. (Jimmy)
Jimmy’s statement echoes participants’ attitude at the 
beginning of the journey where the sense of perseverance 
and hope prevailed. Although he highlights his status of a 
guinea pig here, he does not oppose it; moreover, he chooses 
to give DAAs a ‘bash’. Becoming a test subject seems to be 
necessary to survive. A strong need to overcome the HCV 
pushes him towards unknown treatments, but his willing-
ness is not unconditional. Readiness to try anything is jux-
taposed with a need to protect and preserve the new liver.
Participants identified multiple factors that they imag-
ined could prevent adherence to DAAs. These included 
organ rejection, side effects or uncertainty about DAAs 
effectiveness in post-transplant patients. Participants imag-
ined these obstacles and contraindications for the new ther-
apy in order to protect themselves from disappointment and 
frustration if the INF-free treatment failed. Furthermore, 
captured in unspecified ‘holdup’ while awaiting new treat-
ment, five of the participants in this study started raising 
questions and expressing their doubts:
They’ve said they’ve come up with quite a new drug [DAAs] 
that I’ll go on and I’m still waiting. From what I’ve read is it’s 
been successful. […] I think it’ll be better to speak to somebody 
who’s had the treatment. Doctors have these long words and I 
can’t understand them. I think the not knowing is more of a 
worry than having the illness. They could explain more 
possibilities and what could go wrong here, and they don‘t 
seem to get that out. It just seems to be figures. I’ll ask him (the 
doctor) next time I see him because it’ll be six months since 
I’ve last seen him and he said I was getting put on it and I’m 
still waiting. (Chris)
Chris’ description of lack of information provision and 
need for answers seemed to reveal how little many patients 
knew about treatment that was already licensed and imple-
mented. This gap in knowledge evoked concerns and spec-
ulations that led to nothing but another limbo. Therefore, 
they appeared to enquire into the circumstances of the deci-
sion-making regarding the new treatments:
For me there’s not much evidence on the post-transplant 
because … they are concentrating on the pre-transplant … I 
don’t know if one comes into that cos obviously, they’ve taken 
cleared that before transplant and they wouldn’t have crossed 
the transplant, they wouldn’t have crossed all the drugs after 
that… (Gus)
Although there was a sense of disappointment and frus-
tration regarding lack of evidence on post-transplant treat-
ment in some exerts, it did not imply any unfair approach to 
the post-transplant patients, but it only reflected their scarce 
knowledge about the new treatment.
Two participants who had completed DAAs-based treat-
ment post-transplant and had cleared the recurred virus suc-
cessfully reported being initially seriously ill after receiving 
it. In their retrospective account of this time, a sense of 
determination and hope of being ‘virus-free’ supported 
their adherence to the course of treatment. Despite treat-
ment-related adversities, they were still ‘hoping for the 
best’ and kept their ‘faith’ all along. When the treatment 
was considered successful, a sense of freedom was reported, 
giving birth to a new, healthy identity:
After it was clear [virus-free] I was a different person because 
that was always hanging over me after the transplant. There’s 
a shadow, a thing on the new liver, the hepatitis C was attacking 
it, once I got clear, different, great, so it was. (Steve)
At the time of the interview, only two participants had 
the viral rebound successfully treated with DAAs and had 
been able to identify themselves with the new ‘cured self’. 
However, what unified the experiences of all the partici-
pants was a sense of determination, and often desperation 
accompanied their need to ‘get rid of the virus’. There 
seemed to be nothing that would prevent them from engag-
ing in a ‘trial and error’ approach to treatment or assuming 
the role of ‘guinea pig’, so long that would mean to them 
avoiding more invasive treatment options and saving their 
new liver.
Discussion
This study is novel in exploring the journey of prolonged 
treatment uncertainty in a group of individuals living with 
HCV recurrence after receiving a liver transplant. To date, 
only one qualitative study has addressed the lived experi-
ence of INF-free HCV treatments (Whiteley et al., 2016). 
However, no studies have specifically aimed to capture 
how this ‘new cure’ impacts the lives of post-transplant 
Krzeczkowska et al. 7
patients with virus recurrence. This project thus extends the 
HCV literature on new antiviral therapy, both in post-trans-
plant patients who have already received and cleared the 
virus as well as in those who have yet to be offered the 
treatment.
This study is unique in terms of capturing patients’ lives 
on the edge of treatment development. Surviving a decade-
long passage of unsuccessful treatments resulted in accu-
mulating fears that now cast over patients’ hopes about 
recovery. Those who are still awaiting referrals to DAAs 
regimens are extremely vulnerable and fragile. Knowing 
that there is an effective cure that they can’t simply get 
access to seems to increase their emotional strain and sense 
of helplessness. All seven men in this study have been re-
diagnosed with recurrent HCV post transplant and then 
have ridden the crest of a breaking wave in relation to treat-
ment development, trial work and for some eventual suc-
cess. Their accounts might illuminate the experience of 
other patients who have lived with chronic illness for years 
and suddenly have to re-examine their future in conse-
quence of full recovery following biomedical treatment 
development.
Hope for an ultimate cure remained a crucial determi-
nant in their participation in HCV regimens (Hill et al., 
2014). This positive attitude counterpoised the uncertainty 
and even past experience of highly detrimental INF-α treat-
ment that was found to cast ‘a shadow’ over the new INF-
free regimens (Whiteley et al., 2016). However, this 
dissonance between past and future treatment that evoked 
uncertainty and doubts could be alleviated, if sufficient 
information and support from health care professionals had 
been provided (Bailey et al., 2009). This study builds on 
previous research, which described that patients can feel 
diminished as an individual by the lack of sufficient infor-
mation (Harris, 2005; Hill et al., 2014). Moreover, lack of 
effective ways to communicate knowledge regarding new 
antiviral treatments and their side effects resulted in partici-
pants’ speculations and caused additional distress that was 
previously reported in relation to HCV (Fry and Bates, 
2012).
A state of sustained uncertainty was described in this 
study by five participants who had not yet received the 
‘new cure’ (i.e. DAAs). This ongoing burden reduced their 
ability to incorporate HCV into their lives and accept their 
new illness identity. Thus, unlike previous evidence that 
showed that this kind of successful accommodation of 
HCV might be achievable (Sutton and Treloar, 2007), this 
study indicated that for many, a healthy life transition can 
be rather impossible. The uncertainty of living with a recur-
rent virus appears to prevent a full adjustment to life with 
HCV and the prospect of receiving new treatment suspends 
accommodation. These aspects of sustained uncertainty in 
post-transplant population with HCV have not been previ-
ously identified.
Conversely, two participants who had already received 
the new treatment and cleared the virus experienced a sense 
of liberation and complete control over their future. Thus, 
this study has also demonstrated how a limited framework 
of uncertainty, that is related to the diagnosis of a chronic 
illness (Bury, 1982), can suddenly shift towards a frame-
work of possibilities and future certainty when a sense of 
healthy identity is regained through successful outcomes of 
treatment. Therefore, five of pre-treatment participants had 
great expectations for recovery and, despite their uncertain-
ties, the importance to conquer the condition and survive 
dominated their decision-making (Hopwood and Treloar, 
2005; Sgorbini et al., 2009). Their whole lives represented 
an endless ontological crisis defined by treatment choices 
or their lack.
It is important to highlight the limitations of this study. 
First, in relation to recruitment, the access to participants 
was gained exclusively through only one hospital-based 
outpatient clinic, and at its initial stage, direct involvement 
of the researchers was not permitted. Second, this study 
was exclusively focused on the population with HCV in 
Scotland; therefore, the findings can only be generalized to 
other regions, if similar methods of therapy are used and 
similar population with HCV is treated. Furthermore, par-
ticipants who received the INF-free treatment were not able 
to indicate specifically which INF-free therapy they were 
prescribed, but investigating the differences between new 
therapies was not an aim of this study. However, subse-
quent research might provide more insight regarding differ-
ent treatments and their impact on patients’ perception of 
HCV therapy and their experience of transition to life with-
out HCV.
The implications of this study lie in the potential for 
improvement in the quality of life of post-transplant 
patients with recurrent HCV, who are awaiting new treat-
ment. Considering participants’ scarce knowledge about 
the INF-free therapy and their escalating concerns regard-
ing its side effects and effectiveness, more information 
should be provided through face-to-face consultations 
with their health care providers. Learning more about the 
current and anticipated treatments would lessen a sense of 
being ‘a guinea pig’ in a set of experimental trials and help 
participants regain their sense of control over their illness. 
Developing different psychoeducational groups that are 
specifically tailored for population with HCV would offer 
reassurance and allow to address specific needs that differ 
at specific stages of treatment. Those groups would aim at 
helping patients and their primary caregivers to prepare to 
initiate HCV treatments and cope effectively with their 
consequences. They could be delivered as complementary 
informational sessions, a form of support group meetings 
run by medical professional and where patients could 
share their uncertainties in order to ‘normalize’ and 
authenticate their fears.
8 Health Psychology Open 
Health psychology could respond to complex needs of 
patients with HCV by developing a model that would 
encompass treatment-related beliefs and fears – factors 
impacting adherence and solutions for reducing barriers to 
adequate health care. This model may also constitute a 
foundation for rebuilding a well-functioning patient–physi-
cian relationship and facilitate an efficient communication 
that had been challenged over the course of prolonged 
treatment. The analysis of subsequent stages of HCV treat-
ment revealed also the need of providing counselling and 
HCV-specific psychological interventions along the course 
of prolonged HCV therapy.
Despite significant effectiveness and very minimal 
adverse effects of INF-free treatment, it still remains an 
emotionally and physically challenging life disruption for 
patients involved. Therefore, it is essential to highlight the 
importance of professional support that can lessen the bur-
den of receiving and recovering from HCV treatment 
(Sgorbini et al., 2009). Developing a well-structured health 
care plans for outpatient clinics can resolve issues that have 
been raised in his study. Experiences of lack of information 
provision, uncertainty surrounding treatment effectiveness 
and a sense of lack of control over their HCV and decision-
making in relation to HCV treatment might be replaced by 
enhanced confidence and improved health behaviours if a 
framework of HCV uncertainties is acknowledged and 
understood (Department of Health, 2005). Ongoing formal 
assessment to identify interventions issues and individual 
needs in patients at various points of HCV treatment is 
recommended.
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